---
schema_version: "secwatch.filing_event.v1"
accession: "0001837607-26-000064"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2026-09-30T12:00:24+00:00"
generated_at: "2026-10-12T13:57:51.925504+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AEON Biopharma FDA Type 2b minutes support ABP-450 biosimilar path; milestone warrants to expire Nov 16, 2026

## Summary
- FDA agreed in principle with two-stage CMAP pharmacodynamic study design in extensor digitorum brevis muscle; AEON plans an IND in Q4 2026 and study start in Q1 2027.
- FDA said Daewoong's prior comparative studies in blepharospasm, upper limb spasticity, glabellar lines and lateral canthal lines may be submitted as supportive evidence, subject to bridging.
- AEON does not intend to start a standalone comparative efficacy study now; it will weigh its analytical, PD and human evidence and return to FDA in 2027 with an integrated package.
- Two-Year Milestone Warrants expire Nov 16, 2026 after AEON determined the Type 2b minutes do not preclude advancement toward a 351(k) BLA, triggering the acceleration clause.
- CEO Rob Bancroft cited a potentially more efficient development program; FDA invited analyses supporting the earlier Phase 2 chronic migraine study for the BLA.

## SEC filing metadata
- accession: 0001837607-26-000064
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2026-09-30T12:00:24+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000183760726000064/0001837607-26-000064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000183760726000064/aeon-20260930x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001837607-26-000064
- JSON: https://secwatch.observer/filing/0001837607-26-000064.json
- Plain text: https://secwatch.observer/filing/0001837607-26-000064.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.